Endometrial mullerian adenosarcoma after toremifene treatment in breast cancer patients: a case report / 부인종양
Journal of Gynecologic Oncology
;
: 269-272, 2010.
Artículo
en Inglés
| WPRIM
| ID: wpr-6889
ABSTRACT
Toremifene is an anti-estrogen which has been shown to be effective in the treatment of breast cancer, and is thought to be a less uterotrophic agent than tamoxifen. The risk assessment concerning endometrial cancer has been inconclusive because of its rare use up to the mid-1990s. We report a case of an adenosarcoma, which is a very rare type of uterine malignancy, after toremifene treatment for 5 years in a breast cancer patient. After 1 year of toremifene use, the patient had a benign Mullerian adenofibroma. After an additional 4 years of toremifene treatment, the endometrial polypoid lesion was transformed into a Mullerian adenosarcoma. Although toremifene is a promising anti-estrogenic agent in the treatment of breast cancer patients, clinicians should not neglect the possibility of a uterine malignancy.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Tamoxifeno
/
Mama
/
Neoplasias de la Mama
/
Adenofibroma
/
Neoplasias Endometriales
/
Toremifeno
/
Adenosarcoma
/
Medición de Riesgo
Tipo de estudio:
Estudio de etiología
/
Factores de riesgo
Límite:
Femenino
/
Humanos
Idioma:
Inglés
Revista:
Journal of Gynecologic Oncology
Año:
2010
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS